ClinicalTrials.gg
CompletedNCT01606189Updated Jan 10, 2023Results posted

A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain

A Phase 3 interventional study of GW-1000-02 and GW-2000-02 in Pain, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.

Enrollment
15th of 17
48 · median 246
Started
2001
the only one that year
Phase 3
15 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
14 of 17
Jazz Pharmaceuticals

Among the 17 studies testing nabiximols in Pain, this one is the 15th largest by enrollment, is the only one that started in 2001, is one of 15 in phase 3, and was the 16th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →

About nabiximols

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing nabiximols in Pain as a file.
02

Study summary

A study to compare the efficacy of two sublingual cannabinoid based medicine extracts with placebo in the treatment of chronic pain due to brachial plexus injury.

Read the detailed description

This study used a three way crossover study design. Eligible patients recorded their symptoms during a one to two week baseline period, then entered a three period, double blind, randomised crossover of GW-1000-02, GW-2000-02 and placebo. Each period lasted two weeks, with no washout between periods. There were six possible treatment sequences. The primary analysis was based on Box Scale-11 pain severity scores recorded throughout the study in patient daily diary booklets. Blood samples were taken from patient-volunteers at the beginning of each period, for measurement of plasma cannabinoid concentration.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or above.
  • Brachial plexus pain, at least 18 months after the initial injury.
  • Reported weekly brachial plexus pain at the required severity at Visits 1 and 2; a Box Scale-11 pain severity score of four boxes or above.
  • A pattern of pain that in the Investigator's opinion had been stable during the four weeks before study entry.
  • Stable regular medication during the four weeks before study entry.
  • A maximum tricyclic antidepressant dose of 75 mg per day, if applicable.
  • No cannabinoid use (cannabis, Marinol® or Nabilone) at least seven days before study entry or during the study.
  • If sexually active; was either using effective during the study and for three months thereafter or had been surgically sterilised or, if female, was . All patients agreed to use a barrier method of contraception in addition to their usual form of oral or depot contraception.
  • Willing and able to undertake and comply with all study requirements.
  • Willing and able to consider and understand the patient information leaflet and consent form and to give . Those patients unable to read or to sign the document were managed as detailed in the Declaration of Helsinki.
  • Willing for his or her general practitioner, and consultant if appropriate, to be informed of study participation.
  • Willing for his or her name to be notified to Home Office for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Abuse or strong suspicion of drug abuse, including alcohol or cannabis, or in the investigator's opinion had a tendency to drug dependency or substance abuse. Patients with a history of abuse could have been included at the discretion of the investigator.
  • Known or suspected adverse reaction to cannabinoids.
  • Known or suspected to cannabinoids or any of the of the study medication.
  • History of any type of schizophrenia, any other psychotic illness, or other significant psychiatric illness other than depression associated with chronic illness.
  • Regular levodopa therapy (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®) within seven days of study entry.
  • Serious cardiovascular disorder including recent angina, uncontrolled hypertension or an uncontrolled symptomatic cardiac arrhythmia.
  • History of significant renal or hepatic impairment as shown in medical history or indicated by clinical laboratory results from samples.
  • History of active epilepsy or convulsions.
  • Nerve surgery within six months of study entry or any other surgery within two months of study entry.
  • Elective surgery, other procedures requiring general anaesthesia, or a planned hospital admission that would have taken place during the study, other than a hospital admission under the care of the study investigator.
  • Terminal illness.
  • Pregnancy, lactation or expected non-compliance with the measures called for by the protocol.
  • Participation in any other pharmacological clinical research study in the 12 weeks before study entry.
  • Planned travel outside the UK between study entry and the end of the crossover phase.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    GW-1000-02

    Active treatment.

    Drug: GW-1000-02

  • Experimental
    GW-2000-02

    Active treatment.

    Drug: GW-2000-02

  • Placebo comparator
    Placebo

    Placebo control.

    Drug: Placebo

Interventions

  • Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.

    Also known as: Sativex

  • DrugGW-2000-02

    Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.

  • DrugPlacebo

    Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days)

    Each day patients recorded in their patient diary, the severity of their pain during the previous 24 hours using a Box Scale-11 pain score ranging from zero "no pain at all" to 10 "pain as bad as you can imagine". The Box Scale-11 pain score endpoint for each assessment period was the average of all available data recorded during the seven whole days prior to the visit immediately subsequent to that period, but only including data from Day 8 onwards. A negative value indicates an improvement in pain score from baseline.

    Time frame: Up to 74 days

Secondary outcomes

  1. Change From Baseline in the Mean Sleep Disturbance Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

    Each day patients recorded in their patient diary the number of times they were woken due to pain during the previous night. The results were recorded as "None", "Once", "Twice" and "More Than Twice" and converted to a four point scale, zero to three respectively. The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A negative value indicates an improvement from baseline.

    Time frame: Up to 74 days

  2. Change From Baseline in the Mean Box Scale-11 Sleep Quality Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

    Each day patients recorded in their patient diary the quality of their sleep during the previous night using a Box Scale-11 sleep score ranging from zero "Worst Imaginable" to 10 "Best Imaginable". The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A positive value indicates an improvement from baseline.

    Time frame: Up to 74 days

  3. Change From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days)

    Part 1 of the questionnaire related to the intensity of 15 different types of pain. Intensity was recorded separately for each type of pain on a zero to three scale, where zero = "None", one = "Mild", two = "Moderate" and three = "Severe". The total intensity was defined as the unweighted sum of the 15 scores, giving a minimum possible score of zero (lowest pain score) and a maximum possible score of 45 (highest pain score). The distribution of each of the 15 types of pain was summarised at baseline and for each treatment. A negative value indicates an improvement in pain from baseline.

    Time frame: Up to 74 days

  4. Change From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days)

    Part 2 of the questionnaire recorded the intensity of pain at present. Results were recorded on a VAS ranging from zero "No pain" to 100 "Worst possible pain". Intensity of pain was summarised and analysed in the same manner as the primary efficacy parameter of Box Scale-11 pain score. A negative value indicates an improvement from baseline.

    Time frame: Up to 74 days

  5. Change From Baseline in the Number of Patients Who Reported 'No Pain' or 'Mild Pain' Using a McGill Pain Questionnaire Part 3 Score for 'Strength of Pain at Present' at the End of Each Treatment Period (Each Lasting 14-20 Days)

    Part 3 of the questionnaire recorded the strength of pain at present. Results were recorded in six categories which were classified as "No Pain", "Mild", "Discomforting", "Distressing", "Horrible" and "Excruciating". The change from baseline in the number of patients who reported "No Pain" or "Mild Pain" at the end of the respective treatment periods is presented. An increase in number indicates an improvement from baseline.

    Time frame: Up to 74 days

  6. Change From Baseline in the Mean Pain Disability Index Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

    The Pain Disability Index consisted of seven assessments representing different aspects of disability due to pain. Each assessment was scored on a zero to 10 scale, where zero equated with "no disability" and 10 equated with "total disability". The total Pain Disability Index score was the unweighted sum of the seven pain scores, ranging from zero to 70. A negative value indicates an improvement from baseline.

    Time frame: Up to 74 days

  7. Change From Baseline in the Mean 12-Item General Health Questionnaire Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

    The 12-Item General Health Questionnaire consisted of 12 general health questions. Each question was scored on a zero to three scale, where zero represented the better assessment. The total score was the unweighted sum of the 12 scores, ranging from zero to 36. A negative value indicates an improvement from baseline.

    Time frame: Up to 74 days

  8. Incidence of Adverse Events as a Measure of Patient Safety.

    The number of patients who experienced an adverse event during the course of study is presented.

    Time frame: Up to 114 days

07

Results

Posted Nov 19, 2012

Participant flow

First Intenvention (14-20 Days)
Participant flow — First Intenvention (14-20 Days)
MilestoneGW-1000-02 First, Then GW-2000-02, Then PlaceboGW-2000-02 First, Then GW-1000-02, Then PlaceboPlacebo First, Then GW-1000-02, Then GW-2000-02GW-1000-02 First, Then Placebo, Then GW-2000-02Placebo First, Then GW-2000-02, Then GW-1000-02GW-2000-02 First, Then Placebo, Then GW-1000-02
Started888888
Completed888888
Not completed000000
Second Intenvention (14-20 Days)
Participant flow — Second Intenvention (14-20 Days)
MilestoneGW-1000-02 First, Then GW-2000-02, Then PlaceboGW-2000-02 First, Then GW-1000-02, Then PlaceboPlacebo First, Then GW-1000-02, Then GW-2000-02GW-1000-02 First, Then Placebo, Then GW-2000-02Placebo First, Then GW-2000-02, Then GW-1000-02GW-2000-02 First, Then Placebo, Then GW-1000-02
Started888888
Completed888887
Not completed000001
Withdrew: Adverse event000001
Third Intenvention (14-20 Days)
Participant flow — Third Intenvention (14-20 Days)
MilestoneGW-1000-02 First, Then GW-2000-02, Then PlaceboGW-2000-02 First, Then GW-1000-02, Then PlaceboPlacebo First, Then GW-1000-02, Then GW-2000-02GW-1000-02 First, Then Placebo, Then GW-2000-02Placebo First, Then GW-2000-02, Then GW-1000-02GW-2000-02 First, Then Placebo, Then GW-1000-02
Started888887
Completed888886
Not completed000001
Withdrew: Withdrawal by subject000001

Outcome measures

PrimaryChange From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days)

Each day patients recorded in their patient diary, the severity of their pain during the previous 24 hours using a Box Scale-11 pain score ranging from zero "no pain at all" to 10 "pain as bad as you can imagine". The Box Scale-11 pain score endpoint for each assessment period was the average of all available data recorded during the seven whole days prior to the visit immediately subsequent to that period, but only including data from Day 8 onwards. A negative value indicates an improvement in pain score from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days)
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days)-0.6 ± 1.13-0.6 ± 1.340.0 ± 1.23
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.005 · Estimated mean treatment difference: -0.58 · 95% CI -0.98 to -0.18
  • GW-2000-02 vs Placebo · ANOVA · p = 0.002 · Estimated mean treatment difference: -0.64 · 95% CI -1.03 to -0.24
SecondaryChange From Baseline in the Mean Sleep Disturbance Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

Each day patients recorded in their patient diary the number of times they were woken due to pain during the previous night. The results were recorded as "None", "Once", "Twice" and "More Than Twice" and converted to a four point scale, zero to three respectively. The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A negative value indicates an improvement from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Sleep Disturbance Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean Sleep Disturbance Score at the End of Each Treatment Period (Each Lasting 14-20 Days).-0.2 ± 0.43-0.4 ± 0.510.0 ± 0.47
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.017 · Estimated mean treatment difference: -0.20 · 95% CI -0.37 to -0.04
  • GW-2000-02 vs Placebo · ANOVA · p = <0.001 · Estimated mean treatment difference: -0.33 · 95% CI -0.49 to -0.16
SecondaryChange From Baseline in the Mean Box Scale-11 Sleep Quality Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

Each day patients recorded in their patient diary the quality of their sleep during the previous night using a Box Scale-11 sleep score ranging from zero "Worst Imaginable" to 10 "Best Imaginable". The treatment days and the assessment periods were defined in the same way as for the Box Scale-11 pain score. A positive value indicates an improvement from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Box Scale-11 Sleep Quality Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean Box Scale-11 Sleep Quality Score at the End of Each Treatment Period (Each Lasting 14-20 Days).0.9 ± 1.221.2 ± 1.390.4 ± 1.40
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.019 · Estimated mean treatment difference: 0.55 · 95% CI 0.09 to 1.01
  • GW-2000-02 vs Placebo · ANOVA · p = 0.001 · Estimated mean treatment difference: 0.79 · 95% CI 0.33 to 1.24
SecondaryChange From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days)

Part 1 of the questionnaire related to the intensity of 15 different types of pain. Intensity was recorded separately for each type of pain on a zero to three scale, where zero = "None", one = "Mild", two = "Moderate" and three = "Severe". The total intensity was defined as the unweighted sum of the 15 scores, giving a minimum possible score of zero (lowest pain score) and a maximum possible score of 45 (highest pain score). The distribution of each of the 15 types of pain was summarised at baseline and for each treatment. A negative value indicates an improvement in pain from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days)
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean McGill Pain Questionnaire Part 1 Score for 'Total Pain Intensity' at the End of Each Treatment Period (Each Lasting 14-20 Days)-3.2 ± 8.91-3.8 ± 9.37-1.8 ± 9.26
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.146 · Estimated mean treatment difference: -1.55 · 95% CI -3.64 to 0.55
  • GW-2000-02 vs Placebo · ANOVA · p = 0.040 · Estimated mean treatment difference: -2.20 · 95% CI -4.29 to -0.10
SecondaryChange From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days)

Part 2 of the questionnaire recorded the intensity of pain at present. Results were recorded on a VAS ranging from zero "No pain" to 100 "Worst possible pain". Intensity of pain was summarised and analysed in the same manner as the primary efficacy parameter of Box Scale-11 pain score. A negative value indicates an improvement from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days)
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean McGill Pain Questionnaire Part 2 Score for 'Intensity of Pain' at the End of Each Treatment Period (Each Lasting 14-20 Days)-14.9 ± 25.15-17.3 ± 26.74-8.0 ± 26.92
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.092 · Estimated mean treatment difference: -7.28 · 95% CI -15.78 to 1.21
  • GW-2000-02 vs Placebo · ANOVA · p = 0.037 · Estimated mean treatment difference: -8.99 · 95% CI -17.41 to -0.57
SecondaryChange From Baseline in the Number of Patients Who Reported 'No Pain' or 'Mild Pain' Using a McGill Pain Questionnaire Part 3 Score for 'Strength of Pain at Present' at the End of Each Treatment Period (Each Lasting 14-20 Days)

Part 3 of the questionnaire recorded the strength of pain at present. Results were recorded in six categories which were classified as "No Pain", "Mild", "Discomforting", "Distressing", "Horrible" and "Excruciating". The change from baseline in the number of patients who reported "No Pain" or "Mild Pain" at the end of the respective treatment periods is presented. An increase in number indicates an improvement from baseline.

Time frame:
Up to 74 days
Reported as:
Number · participants
Change From Baseline in the Number of Patients Who Reported 'No Pain' or 'Mild Pain' Using a McGill Pain Questionnaire Part 3 Score for 'Strength of Pain at Present' at the End of Each Treatment Period (Each Lasting 14-20 Days)
participantsGW-1000-02GW-2000-02Placebo
Change From Baseline in the Number of Patients Who Reported 'No Pain' or 'Mild Pain' Using a McGill Pain Questionnaire Part 3 Score for 'Strength of Pain at Present' at the End of Each Treatment Period (Each Lasting 14-20 Days)443
Statistical analysis
  • GW-1000-02 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.328 · Mann-whitney u statistic: 1222.0
  • GW-2000-02 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.560 · Mann-whitney u statistic: 1200.5
SecondaryChange From Baseline in the Mean Pain Disability Index Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

The Pain Disability Index consisted of seven assessments representing different aspects of disability due to pain. Each assessment was scored on a zero to 10 scale, where zero equated with "no disability" and 10 equated with "total disability". The total Pain Disability Index score was the unweighted sum of the seven pain scores, ranging from zero to 70. A negative value indicates an improvement from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean Pain Disability Index Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean Pain Disability Index Score at the End of Each Treatment Period (Each Lasting 14-20 Days).-5.3 ± 9.97-3.1 ± 10.37-3.6 ± 7.69
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.181 · Estimated mean treatment difference: -1.75 · 95% CI -4.32 to 0.83
  • GW-2000-02 vs Placebo · ANOVA · p = 0.739 · Estimated mean treatment difference: 0.43 · 95% CI -2.12 to 2.98
SecondaryChange From Baseline in the Mean 12-Item General Health Questionnaire Score at the End of Each Treatment Period (Each Lasting 14-20 Days).

The 12-Item General Health Questionnaire consisted of 12 general health questions. Each question was scored on a zero to three scale, where zero represented the better assessment. The total score was the unweighted sum of the 12 scores, ranging from zero to 36. A negative value indicates an improvement from baseline.

Time frame:
Up to 74 days
Reported as:
Mean · units on a scale
Change From Baseline in the Mean 12-Item General Health Questionnaire Score at the End of Each Treatment Period (Each Lasting 14-20 Days).
units on a scaleGW-1000-02GW-2000-02Placebo
Change From Baseline in the Mean 12-Item General Health Questionnaire Score at the End of Each Treatment Period (Each Lasting 14-20 Days).-2.2 ± 6.70-1.2 ± 6.120.1 ± 3.92
Statistical analysis
  • GW-1000-02 vs Placebo · ANOVA · p = 0.015 · Estimated mean treatment difference: -2.23 · 95% CI -4.01 to -0.45
  • GW-2000-02 vs Placebo · ANOVA · p = 0.178 · Estimated mean treatment difference: -1.21 · 95% CI -2.97 to 0.56
SecondaryIncidence of Adverse Events as a Measure of Patient Safety.

The number of patients who experienced an adverse event during the course of study is presented.

Time frame:
Up to 114 days
Reported as:
Number · participants
Incidence of Adverse Events as a Measure of Patient Safety.
participantsGW-1000-02GW-2000-02Placebo
Incidence of Adverse Events as a Measure of Patient Safety.343720

Adverse events

Collected over All adverse events occurring from the study onset to up to 40 days follow-up (up to 114 days) were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GW-1000-02—1/46 (2.2%)34/46 (73.9%)
GW-2000-02—0/47 (0%)37/47 (78.7%)
Placebo—0/48 (0%)20/48 (41.7%)
Most frequent serious events
Most frequent serious events
EventGW-1000-02GW-2000-02Placebo
ArthralgiaMusculoskeletal and connective tissue disorders1/460/470/48
Most frequent other events
Showing 10 of 23
Most frequent other events
EventGW-1000-02GW-2000-02Placebo
DizzinessNervous system disorders9/4611/474/48
DysgeusiaNervous system disorders10/465/470/48
SomnolenceNervous system disorders7/466/475/48
Headache Not Otherwise SpecifiedNervous system disorders0/465/470/48
NauseaGastrointestinal disorders0/465/473/48
Feeling DrunkGeneral disorders4/464/470/48
Pain ExacerbatedGeneral disorders0/464/470/48
Throat IrritationRespiratory, thoracic and mediastinal disorders2/464/470/48
Oral DiscomfortGastrointestinal disorders0/460/474/48
Dry MouthNervous system disorders3/463/470/48

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Treatments: GW-1000-02, GW-2000-02 and Placebo
<=18 years0
Between 18 and 65 years48
>=65 years0
Age, Continuous
Age, Continuous(years)All Study Treatments: GW-1000-02, GW-2000-02 and Placebo
Mean38.53 ± 10.342
Sex: Female, Male
Sex: Female, Male(Participants)All Study Treatments: GW-1000-02, GW-2000-02 and Placebo
Female2
Male46
Region of Enrollment
Region of Enrollment(participants)All Study Treatments: GW-1000-02, GW-2000-02 and Placebo
United Kingdom48
08

Study locations

1 site
  • The Royal National Orthopaedic Hospital
    Middlesex, HA7 4LP, United Kingdom
09

References and documents

Publications

  • Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004 Dec;112(3):299-306. doi: 10.1016/j.pain.2004.09.013. PubMed 15561385 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2001, a primary completion of Sep 2002 and a completion of Sep 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 10 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2012
First posted
May 25, 2012
Start
Dec 2001
Primary completionActual
Sep 2002
CompletionActual
Sep 2002
Results first posted
Nov 19, 2012
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01606189
Responsible party
Sponsor
First posted
May 25, 2012
Start date
Dec 2001
Primary completion
Sep 2002
Completion
Sep 2002
Results posted
Nov 19, 2012
Last update
Jan 10, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nabiximols

Start the discussion